Technical Articles

Since the innovation of PD-1/PD-L1 inhibitors in tumor treatment, the search for innate immune regulatory targets has become a key direction to overcome the limitations of existing therapies. The CD47 signaling regulatory protein alpha (SIRP alpha, also known as SHPS1) axis is considered a potential target in the field of tumor immunity due to its regulation of the "self recognition" function of innate immune cells such as macrophages.

SHPS1 (SHP substrate 1), also known as SIRPα (Signal Regulatory Protein α), is a member of the immunoglobulin superfamily and is mainly expressed on the surface of myeloid cells such as macrophages and dendritic cells. Its intracellular segment contains an immunoreceptor tyrosine inhibitory motif (ITIM), which can recruit tyrosine phosphatases SHP-1 and SHP-2 to regulate downstream signaling pathways.